

Polymethylmethacrylate: Properties and Contemporary Uses in Orthopaedics

Todd Jaebon, DO

Abstract

Polymethylmethacrylate (PMMA) has been used in orthopaedics since the 1940s. Despite the development and popularity of new biomaterials, PMMA remains popular. Although its basic components remain the same, small proprietary and environmental changes create variations in its properties. PMMA can serve as a spacer and as a delivery vehicle for antibiotics, and it can be placed to eliminate dead space. Endogenous and exogenous variables that affect its performance include component variables, air, temperature, and handling and mixing. PMMA is used in hip arthroplasty and vertebral augmentation, notably, vertebroplasty and kyphoplasty. Cardiopulmonary complications have been reported.

History

Otto Röhm is credited with the development of polymethylmethacrylate (PMMA) in 1901.¹ A dough-like, workable form of PMMA was refined by the Kulzer and Degussa companies in 1943.² Their developments led to the introduction of cold-cured PMMA, which hardens at room temperature.

PMMA attracted interest in the field of orthopaedics in the 1940s with the development of acrylic femoral hemiarthroplasties by Jean and Robert Judet.³ Kiaer and Haboush separately reported using PMMA to affix femoral implants in the early 1950s.⁴ Modern success with and the popularity of PMMA in orthopaedics is attributable to Sir John Charnley, whose work was affected by his exposure to the field of dentistry and his inherent interest in biomaterials.⁴ Charnley's early clinical accomplishments established a foun-

dation for the continued use of PMMA in orthopaedics.

Composition

PMMA is composed of polymer powder and monomer liquid, often supplied in a 2:1 ratio. The monomer, a colorless liquid with a characteristic odor, is packaged in ampules. The liquid components remain relatively constant among commercially available cements. Methylmethacrylate comprises 97% to 99% of the liquid. N,N-dimethyl-p-toluidine acts as an accelerator, making up 0.4% to 2.8% by weight. Traces of hydroquinone (15 to 75 ppm) stabilize the monomer, preventing premature polymerization. The powder is more variable in composition among brands, which contributes to differences in properties. Microspheres of ground PMMA or copolymer contribute to 83% to 99% of the powder. The remaining components in-

From the Department of Orthopaedics, St. Vincent Mercy Medical Center, Toledo, OH, and Ohio University, Athens, OH.

Dr. Jaebon or an immediate family member has received research or institutional support from Stryker and Synthes.

J Am Acad Orthop Surg 2010;18: 297-305

Copyright 2010 by the American Academy of Orthopaedic Surgeons.

clude a radiopacifier, either barium sulfate (BaSO_4) or zirconium dioxide (ZrO_2) (8% to 15% by weight), as well as an initiator, benzoyl peroxide (0.75% to 2.6%). Other variations include the initiator tri-n-butylborane and accelerator 2,5-dimethylhexane-2,5-hydroperoxide (in Bone-mite [Mochida Pharmaceutical, Tokyo, Japan]), chlorophyll dye (in the monomer of Palacos R [Zimmer, Warsaw, IN]), and ethanol and ascorbic acid (in the monomer of CMW [DePuy, Piscataway, NJ]).⁵ Other additives to the powder may include antibiotics or dyes.

Properties

Reaction

Combining powder and liquid monomer initiates an exothermic reaction. Peak temperatures *in vitro* reach 113°C in the anterior cortex of vertebral bodies.⁶ *In vivo* temperatures are reported to be between 40° and 56°C.^{2,7} Methylmethacrylate monomer, the basic building block of PMMA, contains carbon-carbon double bonds, which react with the free radical produced by the activator and initiator. The monomer is free to interact with other monomer molecules, creating a growing polymer chain. The powder initiates polymerization and creates a workable dough.

Curing

Curing is divided into four phases: mixing, sticky, working, and hardening. The mixing phase ends once a homogenous state has been achieved. The sticky phase is distinguished by low viscosity, in which the mixture fails to separate from a gloved finger. In the working phase, the cement can be handled without adherence. The hardening phase is the time in which cement cannot be mixed and forms a solid. Peak temperatures are reached

in this last phase. There is no specific time for each phase, given the wide variation in cements and testing conditions. For most cements, hardening occurs within 10 to 20 minutes.^{8,9} Commercial PMMA can be categorized as high or low viscosity based on which phase predominates during the curing process. Low-viscosity cements have longer sticky phases and shorter working phases. High-viscosity cements have long handling times and a short sticky phase.

Conversion of monomer molecules to fewer long-chain polymer molecules leads to shrinkage of approximately 6% to 7%.^{2,9} Radiopaque material does not participate in the polymerization reaction, and residual monomer polymerizes over several weeks. A consensus of minimal standards for testing and material performance has been developed for acrylic bone cements by the American Society for Testing and Materials and the International Organization for Standardization.¹⁰

Like bone, cured PMMA is strongest in compression and weakest in tension and under shear stress. PMMA has viscoelastic properties, exhibiting greater stiffness at higher strain rates. Its mechanical properties lie between those of cancellous and cortical bone. The bending modulus of PMMA is between 1 and 3 GPa,¹¹⁻¹³ while that of cortical and cancellous bone is between 10 and 20 GPa and 10 and 2,000 MPa, respectively. PMMA has a compressive strength between 85 and 110 MPa, compared with 133 to 193 MPa for cortical bone. The tensile strength of commercial PMMA and cortical bone are 30 to 50 MPa¹¹ and 51 to 133 MPa, respectively.¹²⁻¹⁴ Fatigue strength, creep, and stress relaxation may be more relevant than tensile strength to long-term clinical performance. Fatigue strength is a product of continuous cyclic loading, creep represents deformation under con-

stant load, and stress relaxation represents the changes of stress during constant strain.

Variations

Endogenous, monomer/polymer, and exogenous variables affect *in vitro* and *in vivo* performance of PMMA. Endogenous factors include component variations, formulation ratios, molecular weights, and physical size of the specimen. Exogenous variations include entrapped air, handling and mixing times, water and body fluids, temperature, and sterilization.

Endogenous

PMMA is often the exclusive polymer, but it may be combined with other copolymers.⁹ The molecular weight of the polymer and cured cement influence handling and mechanical properties. Powders with lower molecular weight facilitate diffusion of monomer during mixing but may reduce cement fatigue performance.^{9,13} Antibiotics have become an important additive to PMMA. Although commercial cements are manufactured with antibiotics premixed, hand-mixed preparations are still commonplace. The amount of antibiotic in commercial PMMA is limited to ≤ 1 g, but additions of even >0.5 g to the standard 40 g of powder have been found to significantly affect the mechanical properties of some commercial preparations. Dunne et al¹⁵ reported a significant drop in the mean number of cycles to failure when an additional 0.5 g gentamicin was added to Palacos R. In a comprehensive review of studies examining the properties of antibiotic-loaded cement, Lewis¹⁶ reported compromise of fatigue performance when the mass of antibiotic to total powder expressed as a percentage is ≥ 1.85 . He stated that lack of consensus regarding the biomechanical effects of antibiotic may be the result of variations in mixing and of the

molecular weight of antibiotics used in prior studies. Hsieh et al¹⁷ showed that 8 g antibiotic per 40 g of powder renders cement unformable.

The addition of a radiopacifier allows identification of PMMA radiographically and constitutes 8% to 15% of powder. This fraction has been reported to have a diminishing effect by approximately 8% on overall strength compared with cement without an opacifier.¹⁸ ZrO₂ is reported to have fewer adverse mechanical effects than do cements containing BaSO₄. Ginebra et al¹⁹ showed improved tensile strength and fracture toughness in cements containing ZrO₂ compared with those without an opacifier. Kurtz et al²⁰ found that the addition of 36% BaSO₄ to Simplex P (Stryker, Kalamazoo, MI) decreased tensile strength and fatigue life. Conversely, industrially mixed PMMA and 30% BaSO₄ demonstrated higher tensile strength and fatigue life than did Simplex P and 10% BaSO₄.

Monomer/Polymer

Fewer variations in mechanical and handling properties are attributed to monomer, given its uniform composition among commercial cements, and the surgeon has little control over its elements. The recommended liquid-to-powder ratio is meant to achieve intended handling and mechanical performance and still meet relevant standards. Depending on the planned procedure, this ratio may be altered clinically to achieve the desired handling properties. Using samples of Simplex P, Haas et al⁹ found little effect resulting from their variations on liquid-to-powder ratio. Conversely, Belkoff et al²¹ used the same cement and reported decreased compressive properties and longer curing times as the monomer-to-powder ratio increased from 0.45 mL/g (manufacturer's recommended ratio) to 1.0 mL/g. They attributed

their differences to a larger number of specimens tested.

Exogenous

Air

The effects of air and its impact on porosity are important variables to consider when using PMMA. Whether introduced by mixing and handling or from evaporation of monomer during polymerization, the inclusion of air can have detrimental mechanical effects. This realization resulted in the development of vacuum and centrifugation methods to minimize the effects of air.

Saha and Pal²² found an increase in ultimate compressive strength and energy absorption capacity of 10% to 15% after reducing porosity. Lewis²³ and Kuehn et al¹³ separately reported that the introduction of air and increased porosity shortens the fatigue life of PMMA. Cements with high viscosity may have increased handling times, leading to an increase in air and porosity. Hand mixing introduces air into the cement mixture. Vacuum mixing and centrifugation reduce the introduction of air and, subsequently, porosity,²⁴ but there is no agreement on the virtues of one method versus another. Both methods have been shown to increase fatigue life. Increases in mixing speed have been implicated in porosity development, but this outcome must be weighed against the disadvantages of slower mixing, which results in a less homogenous mixture. The introduction of air and pores affects cement volume, producing voids that reduce shrinkage.^{9,13}

Fluid/Moisture

The influence of water and body fluids on PMMA is significant given its intended physiologic environment, yet these substances are not always incorporated during laboratory testing. De Santis et al²⁵ reported water absorption of 1% to 2% in plain cement,

which was attributed to the polymer network and voids. In vitro experiments have shown that absorption is ongoing over a 4- to 8-week period at body temperature.¹³ Increased water content leads to a decreased modulus of cement and an associated decrease in fatigue life and tensile strength.^{24,26} Lee et al¹⁸ reported an increase in compressive strength of 3% when equilibrium in moisture content is reached; however, the incorporation of blood into cement has been shown to decrease ultimate compressive strength by 8% to 16%. One advantage of circulating blood during implantation is its effect on reducing peak temperatures of polymerization. This may be partly responsible for lower in vivo temperatures. Relative humidity affects cement handling, and decreased working times have been reported with relative humidity >40%.²⁷

Temperature

One commonly manipulated and controversial variable that affects PMMA handling during polymerization is ambient temperature. Higher temperature during mixing increases the rate of polymerization, leading to decreased working and setting times, but with no effect on peak temperature.²⁸ These effects have led to the popularity of prechilling high-viscosity cements to slow polymerization. Concerns regarding this practice include increasing porosity because of a lengthened working time and, ultimately, a compromise in strength.

Sterilization

Commercial sterilization of PMMA powder currently takes two forms: radiation, which is the most prevalent, and ethylene oxide, a more time-consuming and expensive alternative. The two forms of radiation include gamma and beta irradiation. Both have been implicated in reducing the molecular weight of PMMA,

Table 1**Dosing for Hand-mixed Antibiotic Spacers and Beads Per 40 g Polymethylmethacrylate Powder⁵⁹⁻⁶³**

Antibiotic	Dose (g)
Tobramycin	1.2–4.8
Vancomycin	1–6
Gentamicin	40 mg–4.8 g
Cefazolin	4.5–6

resulting in decreased fatigue life and fracture toughness. Ethylene oxide sterilization has no effect on molecular weight.²⁹ At no time should PMMA powder be exposed to resterilization temperatures; this process deactivates benzoyl peroxide, leading to failure of polymerization.^{13,18}

Contemporary Uses

Arthroplasty

PMMA is used to fill voids left by mismatches between host bone and implant, thus creating immediate stability. The transfer and distribution of forces from implant to bone is thereby subject to a more physiologic transition as a result of mechanical properties of PMMA, which approximate bone. PMMA also dampens excessive forces that would otherwise be directly applied to host bone. PMMA has no adhesive properties to implants on a molecular level. It is dependent on surface properties and shape to enhance stability.³⁰ The quality of apposition between the implant-cement and bone-cement interfaces is of paramount importance in determining the longevity of a cemented prosthesis. These interfaces are directly or indirectly affected by surgical technique and loading characteristics as well as by the properties of cement, bone, and implant.

Gravius et al³¹ reported fewer cement mantle cracks and gap defects

with the use of femoral stems that are anatomically formed, collared, and well rounded. An anatomic stem results in a uniform cement mantle, while the collar decreases tensile stresses on the mantle. More cement defects were reported with titanium alloy stems. The defects were attributed to increased stress imparted on the mantle secondary to a lower implant modulus. Clinical studies of the surface characteristics of implanted cemented femoral components have not established a difference in outcomes between polished and pre-coated or matte finishes.³²⁻³⁴ Fewer studies have addressed the effect of implant characteristics on the cement mantle in areas other than the hip. Pittman et al³⁵ found no difference between titanium alloy and cobalt-chromium cemented tibial components but did note that bond strength increased with surface roughness. Maximizing cement-bone contact is important in creating a mechanically sound interface. Enhanced fixation strength of femoral and tibial components is linked to increases in bone porosity and cement penetration into bone.³⁶⁻³⁹

Cement mantle thickness has been shown to affect fatigue resistance, stress transfer, and heat production. Thin cement mantles are associated with lower fatigue resistance. Significant differences have been found by varying thickness by as little as 0.5 mm at the glenoid⁴⁰ and 1.0 mm at the femoral stem.⁴¹ Using a computer-generated model, Terrier et al⁴⁰ calculated an optimal cement mantle thickness of 1.0 to 1.5 mm for the glenoid. In the same study, thicker mantles were found to transfer excessive stress to the cement-bone interface. Increased cement thickness is also accompanied by increased heat production and risk of thermal necrosis. The effect of heat is a function of temperature and time of exposure. Several in vitro studies using standard surgical techniques have reported temperatures

>50°C for 1 minute, the temperature and exposure time considered necessary for bone necrosis, which may lead to prosthetic loosening.⁴²⁻⁴⁵


Cement viscosity has been shown to have effects on each interface, which could affect prosthetic longevity. High-viscosity cement may be more capable of resisting hemodynamic backflow and has demonstrated increased bone penetration and femoral stem apposition.^{46,47} The consequences of porosity in arthroplasty are subject to conflicting data. Janssen et al⁴⁸ and Topoleski et al⁴⁹ reported the unpredictable nature of pores to initiate cracks and to deviate or decelerate cracking. Other authors have demonstrated only adverse effects of porosity, including instability and decreased fracture toughness.^{50,51} Zhang et al⁵² have shown that the brand of cement used, in combination with a polished femoral stem, is the most important factor in determining static shear strength, and that viscosity and porosity play a limited role.

Infection

Two studies separately established the effectiveness of antibiotic delivery via PMMA.^{53,54} PMMA can serve as a delivery vehicle for antibiotic, act as a spacer, and be a filler of dead space, thus eliminating it. Antibiotic-loaded PMMA has been used successfully to manage infected joint arthroplasties, osteomyelitis, and open fractures with bone defects⁵⁵⁻⁶³ (Table 1).

Antibiotics are eluted from the surface and pores of cement as well as from the microcracks within it. Elution characteristics vary by brand. Palacos has demonstrated favorable elution characteristics, and several studies have shown that it is capable of delivering high local concentrations of antibiotics with long elution times.^{61,64,65} The amount of antibiotic

Figure 1



A, Photograph of an open IIIB tibia fracture. **B**, Photograph demonstrating insertion of an antibiotic bead chain following débridement in preparation for a bead pouch.

delivered also depends on the overall surface area of the implant and the characteristics of the antibiotic used. General qualifications for a successful pairing of an antibiotic with PMMA include heat stability during the exothermic reaction, ability to diffuse in water, low potential for allergic reaction, and an appropriate spectrum against potential or confirmed organisms.

Tobramycin and gentamicin are the most frequently used and most studied antibiotics. Vancomycin and cephalosporins continue to be used as well. Tobramycin is popular because it comes in powder form, which is easy to mix, and because of its broad spectrum, which includes antipseudomonal coverage. It has been shown to potentiate the elution of other antibiotics, such as vancomycin.⁶⁶ Gentamicin is often supplied in liquid form, which may have more adverse mechanical effects on cement.⁶⁷ Vancomycin is used for its effectiveness against methicillin-resistant *Staphylococcus aureus* (MRSA) and its low allergenic potential. Some authors have discouraged its routine use except for patients with a demonstrated specific need for MRSA coverage because of concerns regarding the development of resistant organisms during the time of waning concentrations.⁶⁴ Cepha-


losporins can be used with PMMA and have better gram-positive coverage than do tobramycin and gentamicin. McLaren et al⁶⁸ found no difference in average cumulative release of antibiotic, whether first added to a monomer or to PMMA powder. Elution rates of antibiotics, such as gentamicin, have been shown to be adversely affected by hand mixing, possibly because of reduced uniformity of distribution.⁶⁹

Treatment of active infections with antibiotic-loaded PMMA requires eventual removal of the delivery device. Commercially preloaded cements used for prophylaxis are intended to be permanent, and the antibiotic concentration is selected so as not to substantially degrade the mechanical properties of the cement. These cements are US FDA-approved for use in reimplantation arthroplasty after infection and for patients at high risk of infection during primary arthroplasty. None carries a large enough dose of antibiotic to treat active infections. Most are loaded with gentamicin or tobramycin. Spacers also serve to maintain a more physiologic environment with regard to soft-tissue tension and limb alignment until a more definitive procedure can be performed. They facilitate mobility and better exposure during joint reimplantation.^{58,70} Commercial systems, such

as the prosthesis of antibiotic-loaded acrylic cement (PROSTALAC, DePuy), allow greater precision in the creation of an articulating antibiotic spacer.

Antibiotic bead chains have been traditionally used in the management of bone defects associated with osteomyelitis or open fracture. Initially favored because of the large amount of available surface area, difficulty in removal of the beads and soft-tissue intrusion have led some clinicians to use spacers for defects instead (Figures 1 and 2). This method may preserve a more natural avenue for bone reconstruction; it can also be used as a structural strut within the defect. Internal fixation may be anchored into the spacer until bone grafting can be safely performed.

The duration of antibiotic elution in vivo is difficult to characterize. Bertazzoni Minelli et al⁷¹ reported that gentamicin- and vancomycin-loaded cement explants elute at sufficient levels after several months. Most antibiotic implants elute most of their antibiotic by 9 weeks, but they continue to diffuse at sufficient levels for months. Masri et al⁶² reported bactericidal levels of elution at 4 months when tobramycin was combined with vancomycin. Despite often high doses of local antibiotic delivered im-

Figure 2**A****B**

A, Preoperative AP radiograph of an open IIIB forearm fracture. **B**, AP radiograph demonstrating insertion antibiotic spacer radius defect following the third débridement, 96 hours after injury.

mediately after implantation, rare cases of toxicity have been reported. Springer et al⁶³ reported using up to 10.5 g vancomycin and 12.5 g gentamicin without adverse effects. One should be diligent about recognizing the clinical symptoms of toxicity with each individual antibiotic. Appropriate serum levels should be obtained, if necessary.

Spine

Although PMMA is used frequently in the spine, its use has been limited

mostly to vertebral augmentation (VA). Galibert et al⁷² first reported successful results after injecting PMMA in the management of painful hemangiomas of the vertebral body. Pain elimination was accompanied by prevention of further collapse. This application was later used in patients with metastatic disease and myeloma to help prevent collapse of the vertebral body and canal compromise.

Current VA techniques include vertebroplasty and kyphoplasty. Both pro-

cedures focus on stabilization and pain relief through percutaneous transpedicular introduction of PMMA into the vertebral body. Despite recent reports refuting the benefits of vertebroplasty, this technique remains an alternative method of managing osteoporotic compression fractures of the thoracic and lumbar spine.^{73,74} In vertebroplasty, PMMA is injected into the affected vertebral body. In kyphoplasty, a more concerted effort is made to restore vertebral height and, more important, to create a void before the injection to enhance the safe application of PMMA. Although other bioactive materials are available, PMMA is currently favored for the management of VA because of its documented clinical success as well as its structural integrity, handling properties, and radiopacity.

The ability of PMMA to cure rapidly to a mechanically sound state is particularly advantageous in the compromised patient who requires immediate mobilization. Essential PMMA characteristics required for successful execution of VA include radiopacity and optimal viscosity. Radiopacifiers are necessary to allow monitoring for extravasation. Adequate viscosity is essential to enable unimpeded travel during injection yet prevent extravasation from a compromised vertebral body. Lieberman et al⁷⁵ recommended ideal cement states for vertebroplasty and kyphoplasty. Cement with a longer sticky or liquid phase should be considered for vertebroplasty, whereas cement with a short sticky phase and longer working phase is preferred for kyphoplasty.

Commercial preparations of PMMA have emerged with formulations to facilitate use in VA. These cements contain between 15% and 33% by weight of BaSO₄ or ZrO₂. Some contain additional amounts of tungsten or tantalum, neither of which is an approved radiopacifier in the United

States. Mechanical changes as a result of increasing amounts of radioopaque material are varied.^{5,75} Using American Society for Testing and Materials standards, Kurtz et al²⁰ tested commercial preparations of Simplex P with 10% BaSO₄, Simplex P with 36% BaSO₄, and KyphX HV-R (Kyphon, Sunnyvale, CA) with 30% BaSO₄. The authors concluded that the static and fatigue properties of PMMA with elevated BaSO₄ content were enough to withstand loading conditions in the vertebral body.

Restoration of compressive strength and stiffness of the involved vertebra is dependent on the brand of cement, the vertebral level, and possibly, the volume of cement. These factors and variations in testing methods have led to disparate results.⁷⁶⁻⁷⁸ Belkoff et al⁷⁶ reported restoration of compressive strength in PMMA-augmented fracture models using 2 mL cement in the two brands tested. Several authors have shown similar or superior restitution of compressive strength in vertebral fracture models. Others have revealed a decrease in overall stiffness from prefracture levels.^{77,78}

Cardiopulmonary Complications

Cardiopulmonary complications associated with PMMA have been reported in conjunction with hip arthroplasty and VA. Prior studies have postulated that PMMA-associated hypoxia, hypotension, and death may occur as a result of the toxic effects of monomer⁷⁹ or anaphylaxis.⁸⁰ Other literature indicates that the application of PMMA may lead to embolization of marrow debris and neurogenic reflex, thus adversely affecting cardiopulmonary function.⁸¹⁻⁸⁴ Pulmonary infarction and death have been reported as a result of embolization of PMMA that was injected in liquid state following VA.⁸⁵

Summary

Despite widespread utilization, the composition and properties of PMMA are not completely appreciated. Advances in implant interfaces and biomechanics and the development of bioactive materials may alter the role of PMMA in orthopaedics, but it continues to play a vital role, albeit a changing one. PMMA has gained favor as a vehicle for the delivery of antibiotics and for use in VA. Its propensity to act as a structural pharmaceutical repository and slow-release vehicle has made PMMA a powerful tool in the management of complex musculoskeletal infections.

References

Evidence-based Medicine: Levels of evidence are described in the table of contents. In this article, references 31, 72, and 73 are level I studies. References 35 and 82 are level II studies. Reference 33 is a level III study. References 2, 16, 32, 53-58, 62, 69, 71, and 84 are level IV studies. References 3 and 59 are level V expert opinion.

Citation numbers printed in **bold type** indicate references published within the past 5 years.

1. Röhm O: *On the Polymerization Products of Acrylic Acid* [dissertation]. Tübingen, Germany, University of Tübingen, 1901.
2. Kuehn KD, Ege W, Gopp U: Acrylic bone cements: Composition and properties. *Orthop Clin North Am* 2005; 36:17-28.
3. Haboush EJ: A new operation for arthroplasty of the hip based on biomechanics, photoelasticity, fast-setting dental acrylic, and other considerations. *Bull Hosp Joint Dis* 1953;14:242-277.
4. Charnley J: The bonding of prostheses to bone by cement. *J Bone Joint Surg Br* 1964;46:518-529.
5. Lewis G: Alternative acrylic bone cement formulations for cemented

arthroplasties: Present status, key issues, and future prospects. *J Biomed Mater Res B Appl Biomater* 2008;84:301-319.

6. Belkoff SM, Molloy S: Temperature measurement during polymerization of polymethylmethacrylate cement used for vertebroplasty. *Spine (Phila Pa 1976)* 2003;28:1555-1559.
7. Webb JC, Spencer RF: The role of polymethylmethacrylate bone cement in modern orthopaedic surgery. *J Bone Joint Surg Br* 2007;89:851-857.
8. Goodman S: Wear particulate and osteolysis. *Orthop Clin North Am* 2005; 36:41-48, vi.
9. Haas SS, Brauer GM, Dickson G: A characterization of polymethylmethacrylate bone cement. *J Bone Joint Surg Am* 1975;57:380-391.
10. Nottrott M, Mølster AO, Moldstad IO, Walsh WR, Gjerdet NR: Performance of bone cements: Are current preclinical specifications adequate? *Acta Orthop* 2008;79:826-831.
11. Harper EJ, Bonfield W: Tensile characteristics of ten commercial acrylic bone cements. *J Biomed Mater Res* 2000;53:605-616.
12. Miller JD, McCreadie BR, Alford AI, Hankenson KD, Golstein SA: Form and function of bone, in Einhorn TA, O'Keefe RJ, Buckwalter JA, eds: *Orthopaedic Basic Science: Foundations of Clinical Practice*, ed 3. Rosemont, IL, American Academy of Orthopaedic Surgeons, 2007, pp 129-159.
13. Kuehn KD, Ege W, Gopp U: Acrylic bone cements: Mechanical and physical properties. *Orthop Clin North Am* 2005; 36:29-39.
14. Reilly DT, Burstein AH: The elastic and ultimate properties of compact bone tissue. *J Biomech* 1975;8:393-405.
15. Dunne N, Hill J, McAfee P, et al: In vitro study of the efficacy of acrylic bone cement loaded with supplementary amounts of gentamicin: Effect on mechanical properties, antibiotic release, and biofilm formation. *Acta Orthop* 2007;78:774-785.
16. Lewis G: Properties of antibiotic-loaded acrylic cements for use in cemented arthroplasties: A state-of-the-art review. *J Biomed Mater Res B Appl Biomater* 2008;89B:558-574.
17. Hsieh PH, Chen LH, Chen CH, Lee MS, Yang WE, Shih CH: Two-stage revision hip arthroplasty for infection with a custom-made, antibiotic-loaded, cement prosthesis as an interim spacer. *J Trauma* 2004;56:1247-1252.
18. Lee AJ, Ling RS, Vangala SS: Some clinically relevant variables affecting the mechanical behaviour of bone cement.

- Arch Orthop Trauma Surg* 1978;92:1-18.
19. Ginebra MP, Albuixech L, Fernández-Barragán E, et al: Mechanical performance of acrylic bone cements containing different radiopacifying agents. *Biomaterials* 2002;23:1873-1882.
20. Kurtz SM, Villarraga ML, Zhao K, Edidin AA: Static and fatigue mechanical behavior of bone cement with elevated barium sulfate content for treatment of vertebral compression fractures. *Biomaterials* 2005;26:3699-3712.
21. Belkoff SM, Sanders JC, Jasper LE: The effect of the monomer-to-powder ratio on the material properties of acrylic bone cement. *J Biomed Mater Res* 2002;63:396-399.
22. Saha S, Pal S: Mechanical properties of bone cement: A review. *J Biomed Mater Res* 1984;18:435-462.
23. Lewis G: Properties of acrylic bone cement: State of the art review. *J Biomed Mater Res* 1997;38:155-182.
24. Lidgren L, Bodelind B, Möller J: Bone cement improved by vacuum mixing and chilling. *Acta Orthop Scand* 1987;58:27-32.
25. De Santis R, Mollica F, Ambrosio L, Nicolais L, Ronca D: Dynamic mechanical behavior of PMMA based bone cements in wet environment. *J Mater Sci Mater Med* 2003;14:583-594.
26. Nottrott M, Mølster AO, Gjerdet NR: Time dependent mechanical properties of bone cement: An in vitro study over one year. *J Biomed Mater Res B Appl Biomater* 2007;83:416-421.
27. Walenkamp GH, Murray DW, eds: *Bone Cements and Cementing Technique*. Berlin, Germany, Springer-Verlag, 2001.
28. Nicholas MK, Waters MG, Holford KM, Adusei G: Analysis of rheological properties of bone cements. *J Mater Sci Mater Med* 2007;18:1407-1412.
29. Harper EJ, Braden M, Bonfield W, Dingeldein E, Wahlig H: Influence of sterilization upon a range of properties of experimental bone cements. *J Mater Sci Mater Med* 1997;8:849-853.
30. Crowninshield R: Femoral hip implant fixation within bone cement. *Operative Techniques in Orthopaedics* 2001;11:296-299.
31. Gravius S, Wirtz DC, Siebert CH, et al: In vitro interface and cement mantle analysis of different femur stem designs. *J Biomech* 2008;41:2021-2028.
32. Lachiewicz PF, Kelley SS, Soileau ES: Survival of polished compared with precoated roughened cemented femoral components: A prospective, randomized study. *J Bone Joint Surg Am* 2008;90:1457-1463.
33. Callaghan JJ, Liu SS, Firestone DE, et al: Total hip arthroplasty with cement and use of a collared matte-finish femoral component: Nineteen to twenty-year follow-up. *J Bone Joint Surg Am* 2008;90:299-306.
34. Firestone DE, Callaghan JJ, Liu SS, et al: Total hip arthroplasty with a cemented, polished, collared femoral stem and a cementless acetabular component: A follow-up study at a minimum of ten years. *J Bone Joint Surg Am* 2007;89:126-132.
35. Pittman GT, Peters CL, Hines JL, Bachus KN: Mechanical bond strength of the cement-tibial component interface in total knee arthroplasty. *J Arthroplasty* 2006;21:883-888.
36. Lutz MJ, Pincus PF, Whitehouse SL, Halliday BR: The effect of cement gun and cement syringe use on the tibial cement mantle in total knee arthroplasty. *J Arthroplasty* 2009;24:461-467.
37. Mann KA, Miller MA, Cleary RJ, Janssen D, Verdonschot N: Experimental micromechanics of the cement-bone interface. *J Orthop Res* 2008;26:872-879.
38. Graham J, Ries M, Pruitt L: Effect of bone porosity on the mechanical integrity of the bone-cement interface. *J Bone Joint Surg Am* 2003;85:1901-1908.
39. Peters CL, Craig MA, Mohr RA, Bachus KN: Tibial component fixation with cement: Full- versus surface-cementation techniques. *Clin Orthop Relat Res* 2003;409:158-168.
40. Terrier A, Büchler P, Farron A: Bone-cement interface of the glenoid component: Stress analysis for varying cement thickness. *Clin Biomech (Bristol, Avon)* 2005;20:710-717.
41. Cristofolini L, Erani P, Savigni P, Grupp T, Thies O, Viceconti M: Increased long-term failure risk associated with excessively thin cement mantle in cemented hip arthroplasty: A comparative in vitro study. *Clin Biomech (Bristol, Avon)* 2007;22:410-421.
42. Eriksson AR, Albrektsson T: Temperature threshold levels for heat-induced bone tissue injury: A vital-microscopic study in the rabbit. *J Prosthet Dent* 1983;50:101-107.
43. Hsieh PH, Tai CL, Liaw JW, Chang YH: Thermal damage potential during hip resurfacing in osteonecrosis of the femoral head: An experimental study. *J Orthop Res* 2008;26:1206-1209.
44. Churchill RS, Boorman RS, Fehringer EV, Matsen FA III: Glenoid cementing may generate sufficient heat to endanger the surrounding bone. *Clin Orthop Relat Res* 2004;419:76-79.
45. Gill HS, Campbell PA, Murray DW, De Smet KA: Reduction of the potential for thermal damage during hip resurfacing. *J Bone Joint Surg Br* 2007;89:16-20.
46. Race A, Miller MA, Clarke MT, Mann KA, Higham PA: The effect of low-viscosity cement on mantle morphology and femoral stem micromotion: A cadaver model with simulated blood flow. *Acta Orthop* 2006;77:607-616.
47. Miller MA, Race A, Gupta S, Higham P, Clarke MT, Mann KA: The role of cement viscosity on cement-bone apposition and strength: An in vitro model with medullary bleeding. *J Arthroplasty* 2007;22:109-116.
48. Janssen D, Aquarius R, Stolk J, Verdonschot N: The contradictory effects of pores on fatigue cracking of bone cement. *J Biomed Mater Res B Appl Biomater* 2005;74:747-753.
49. Topoleski LD, Ducheyne P, Cuckler JM: Microstructural pathway of fracture in poly(methyl methacrylate) bone cement. *Biomaterials* 1993;14:1165-1172.
50. Ries MD, Young E, Al-Marashi L, et al: In vivo behavior of acrylic bone cement in total hip arthroplasty. *Biomaterials* 2006;27:256-261.
51. Mann KA, Damron LA, Miller MA, Race A, Clarke MT, Cleary RJ: Stem-cement porosity may explain early loosening of cemented femoral hip components: Experimental-computational in vitro study. *J Orthop Res* 2007;25:340-350.
52. Zhang H, Brown L, Blunt L: Static shear strength between polished stem and seven commercial acrylic bone cements. *J Mater Sci Mater Med* 2008;19:591-599.
53. Buchholz HW, Engelbrecht H: Depot effects of various antibiotics mixed with Palacos resins [German]. *Chirurg* 1970;41:511-515.
54. Klemm K: Gentamicin-PMMA-beads in treating bone and soft tissue infections [German]. *Zentralbl Chir* 1979;104:934-942.
55. Thonse R, Conway J: Antibiotic cement-coated interlocking nail for the treatment of infected nonunions and segmental bone defects. *J Orthop Trauma* 2007;21:258-268.
56. Ristiniemi J, Lakovaara M, Flinkkilä T, Jalovaara P: Staged method using antibiotic beads and subsequent autografting for large traumatic tibial bone loss: 22 of 23 fractures healed after 5-20 months. *Acta Orthop* 2007;78:520-527.
57. Hofmann AA, Goldberg TD, Tanner

- AM, Cook TM: Ten-year experience using an articulating antibiotic cement hip spacer for the treatment of chronically infected total hip. *J Arthroplasty* 2005;20:874-879.
58. Hofmann AA, Goldberg T, Tanner AM, Kurtin SM: Treatment of infected total knee arthroplasty using an articulating spacer: 2- to 12-year experience. *Clin Orthop Relat Res* 2005;430:125-131.
 59. Morimoto S, Futani H, Ogura H, Okayama A, Maruo S: Successful reimplantation of total femoral prosthesis after deep infection. *J Arthroplasty* 2003;18:216-220.
 60. Zalavras CG, Patzakis MJ, Holtom P: Local antibiotic therapy in the treatment of open fractures and osteomyelitis. *Clin Orthop Relat Res* 2004;427:86-93.
 61. Cui Q, Mihalko WM, Shields JS, Ries M, Saleh KJ: Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. *J Bone Joint Surg Am* 2007;89:871-882.
 62. Masri BA, Duncan CP, Beauchamp CP: Long-term elution of antibiotics from bone-cement: An in vivo study using the prosthesis of antibiotic-loaded acrylic cement (PROSTALAC) system. *J Arthroplasty* 1998;13:331-338.
 63. Springer BD, Lee GC, Osmon D, Haidukewych GJ, Hanssen AD, Jacofsky DJ: Systemic safety of high-dose antibiotic-loaded cement spacers after resection of an infected total knee arthroplasty. *Clin Orthop Relat Res* 2004;427:47-51.
 64. Jiranek WA, Hanssen AD, Greenwald AS: Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. *J Bone Joint Surg Am* 2006;88:2487-2500.
 65. Stevens CM, Tetsworth KD, Calhoun JH, Mader JT: An articulated antibiotic spacer used for infected total knee arthroplasty: A comparative in vitro elution study of Simplex and Palacos bone cements. *J Orthop Res* 2005;23:27-33.
 66. González Della Valle A, Bostrom M, Brause B, Harney C, Salvati EA: Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement. *Acta Orthop Scand* 2001;72:237-240.
 67. Seldes RM, Winiarsky R, Jordan LC, et al: Liquid gentamicin in bone cement: A laboratory study of a potentially more cost-effective cement spacer. *J Bone Joint Surg Am* 2005;87:268-272.
 68. McLaren AC, Nugent M, Economopoulos K, Kaul H, Vernon BL, McLemore R: Hand-mixed and premixed antibiotic-loaded bone cement have similar homogeneity. *Clin Orthop Relat Res* 2009;467:1693-1698.
 69. Lewis G, Janna S, Bhattaram A: Influence of the method of blending an antibiotic powder with an acrylic bone cement powder on physical, mechanical, and thermal properties of the cured cement. *Biomaterials* 2005;26:4317-4325.
 70. Anderson JA, Sculco PK, Heitkemper S, Mayman DJ, Bostrum MP, Sculco TP: An articulating spacer to treat and mobilize patients with infected total knee arthroplasty. *J Arthroplasty* 2009;24:631-635.
 71. Bertazzoni Minelli E, Caveiari C, Benini A: Release of antibiotics from polymethylmethacrylate cement. *J Chemother* 2002;14:492-500.
 72. Galibert P, Deramond H, Rosat P, Le Gars D: Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty [French]. *Neurochirurgie* 1987;33:166-168.
 73. Buchbinder R, Osborne RH, Ebeling PR, et al: A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. *N Engl J Med* 2009;361:557-568.
 74. Kallmes DF, Comstock BA, Heagerty PJ, et al: A randomized trial of vertebroplasty for osteoporotic spinal fractures. *N Engl J Med* 2009;361:569-579.
 75. Lieberman IH, Togawa D, Kayanja MM: Vertebroplasty and kyphoplasty: Filler materials. *Spine J* 2005;5(6 suppl):305S-316S.
 76. Belkoff SM, Mathis JM, Jasper LE, Deramond H: The biomechanics of vertebroplasty: The effect of cement volume on mechanical behavior. *Spine (Phila Pa 1976)* 2001;26:1537-1541.
 77. Furtado N, Oakland RJ, Wilcox RK, Hall RM: A biomechanical investigation of vertebroplasty in osteoporotic compression fractures and in prophylactic vertebral reinforcement. *Spine (Phila Pa 1976)* 2007;32:E480-E487.
 78. Alkalay RN, von Stechow D, Torres K, Hassan S, Sommerich R, Zurakowski D: The effect of cement augmentation on the geometry and structural response of recovered osteopenic vertebrae: An anterior-wedge fracture model. *Spine (Phila Pa 1976)* 2008;33:1627-1636.
 79. Peebles DJ, Ellis RH, Stride SD, Simpson BR: Cardiovascular effects of methylmethacrylate cement. *Br Med J* 1972;1:349-351.
 80. Nussbaum DA, Gailloud P, Murphy K: A review of complications associated with vertebroplasty and kyphoplasty as reported to the Food and Drug Administration medical device related web site. *J Vasc Interv Radiol* 2004;15:1185-1192.
 81. Krebs J, Ferguson SJ, Hoerstrup SP, Goss BG, Haeberli A, Aebli N: Influence of bone marrow fat embolism on coagulation activation in an ovine model of vertebroplasty. *J Bone Joint Surg Am* 2008;90:349-356.
 82. Krebs J, Aebli N, Goss BG, et al: Cardiovascular changes after pulmonary embolism from injecting calcium phosphate cement. *J Biomed Mater Res B Appl Biomater* 2007;82:526-532.
 83. Hulme PA, Krebs J, Ferguson SJ, Berlemann U: Vertebroplasty and kyphoplasty: A systematic review of 69 clinical studies. *Spine (Phila Pa 1976)* 2006;31:1983-2001.
 84. Aebli N, Krebs J, Davis G, Walton M, Williams MJ, Theis JC: Fat embolism and acute hypotension during vertebroplasty: An experimental study in sheep. *Spine (Phila Pa 1976)* 2002;27:460-466.
 85. Jang JS, Lee SH, Jung SK: Pulmonary embolism of polymethylmethacrylate after percutaneous vertebroplasty: A report of three cases. *Spine (Phila Pa 1976)* 2002;27:E416-E418.